- Home
- BLTE vs OGN Comparison
BLTE vs OGN Comparison
Compare BLTE & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLTE
- OGN
- Stock Information
- Founded
- BLTE 2018
- OGN 1923
- Country
- BLTE United States
- OGN United States
- Employees
- BLTE N/A
- OGN N/A
- Industry
- BLTE Biotechnology: Pharmaceutical Preparations
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- BLTE Health Care
- OGN Health Care
- Exchange
- BLTE Nasdaq
- OGN Nasdaq
- Market Cap
- BLTE 2.1B
- OGN 2.5B
- IPO Year
- BLTE 2022
- OGN N/A
- Fundamental
- Price
- BLTE $68.01
- OGN $9.50
- Analyst Decision
- BLTE Strong Buy
- OGN Hold
- Analyst Count
- BLTE 4
- OGN 4
- Target Price
- BLTE $96.67
- OGN $18.00
- AVG Volume (30 Days)
- BLTE 45.0K
- OGN 4.7M
- Earning Date
- BLTE 08-11-2025
- OGN 08-05-2025
- Dividend Yield
- BLTE N/A
- OGN 0.85%
- EPS Growth
- BLTE N/A
- OGN N/A
- EPS
- BLTE N/A
- OGN 2.69
- Revenue
- BLTE N/A
- OGN $6,281,000,000.00
- Revenue This Year
- BLTE N/A
- OGN N/A
- Revenue Next Year
- BLTE N/A
- OGN $1.02
- P/E Ratio
- BLTE N/A
- OGN $3.49
- Revenue Growth
- BLTE N/A
- OGN N/A
- 52 Week Low
- BLTE $43.70
- OGN $8.01
- 52 Week High
- BLTE $86.53
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- BLTE 59.16
- OGN 47.99
- Support Level
- BLTE $68.99
- OGN $8.93
- Resistance Level
- BLTE $74.49
- OGN $9.43
- Average True Range (ATR)
- BLTE 3.27
- OGN 0.48
- MACD
- BLTE 0.48
- OGN -0.02
- Stochastic Oscillator
- BLTE 61.59
- OGN 51.81
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.